Comment
doi: 10.1200/JCO.21.00810.
Epub 2021 Jun 4.
Reply to A.C. Olson et al, R.T. Dess et al, D.D. Yang et al, and R.J. Brenneman et al
Affiliations
- PMID: 34086489
- DOI: 10.1200/JCO.21.00810
Item in Clipboard
Comment
Reply to A.C. Olson et al, R.T. Dess et al, D.D. Yang et al, and R.J. Brenneman et al
J Clin Oncol.
.
No abstract available
Comment on
-
Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial.J Clin Oncol. 2021 Apr 10;39(11):1234-1242. doi: 10.1200/JCO.20.03282. Epub 2021 Jan 26. J Clin Oncol. 2021. PMID: 33497252 Clinical Trial.
-
End Point Definitions and Surrogacy in Prostate Cancer: Will Metastasis-Free Survival Become Event-Free Survival With Advances in Molecular Imaging?J Clin Oncol. 2021 Sep 1;39(25):2844-2845. doi: 10.1200/JCO.21.00376. Epub 2021 Jun 4. J Clin Oncol. 2021. PMID: 34086486 No abstract available.
-
Regarding the Use of PSMA PET-CT Versus Conventional Imaging for Assessing the Value of Prophylactic Whole-Pelvis Radiation for High-Risk Prostate Cancer.J Clin Oncol. 2021 Sep 1;39(25):2847-2848. doi: 10.1200/JCO.21.00634. Epub 2021 Jun 4. J Clin Oncol. 2021. PMID: 34086488 No abstract available.
-
Elective Pelvic Lymph Node Radiation in Prostate Cancer Revisited.J Clin Oncol. 2021 Sep 1;39(25):2845-2846. doi: 10.1200/JCO.21.00621. Epub 2021 Jun 4. J Clin Oncol. 2021. PMID: 34086490 No abstract available.
-
Is Distant Metastasis-Free Survival Lead Time Bias?J Clin Oncol. 2021 Sep 1;39(25):2844. doi: 10.1200/JCO.21.00326. Epub 2021 Jun 4. J Clin Oncol. 2021. PMID: 34086500 No abstract available.
Similar articles
-
Hydroids (Cnidaria, Hydrozoa) from Mauritanian Coral Mounds.Zootaxa. 2020 Nov 16;4878(3):zootaxa.4878.3.2. doi: 10.11646/zootaxa.4878.3.2. Zootaxa. 2020. PMID: 33311142
-
Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al.J Clin Oncol. 2018 Aug 20;36(24):2567-2569. doi: 10.1200/JCO.2018.78.6418. Epub 2018 Jun 26. J Clin Oncol. 2018. PMID: 29945519 No abstract available.
-
Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al.J Clin Oncol. 2016 Nov 20;34(33):4050-4051. doi: 10.1200/JCO.2016.69.1105. Epub 2016 Oct 31. J Clin Oncol. 2016. PMID: 27551125 No abstract available.
-
Contribution of the plasma and lymph Degradome and Peptidome to the MHC Ligandome.Immunogenetics. 2019 Mar;71(3):203-216. doi: 10.1007/s00251-018-1093-z. Epub 2018 Oct 20. Immunogenetics. 2019. PMID: 30343358 Free PMC article. Review.
-
Neuropeptides as growth and differentiation factors in general and VIP in particular.J Mol Neurosci. 1993 Spring;4(1):1-9. doi: 10.1007/BF02736685. J Mol Neurosci. 1993. PMID: 8318354 Review.
Cited by
-
Narrative review of focal boost to intraprostatic dominant lesion in intensity-modulated radiation therapy for localized or locally advanced prostate cancer.Int J Clin Oncol. 2025 Aug;30(8):1448-1462. doi: 10.1007/s10147-025-02799-x. Epub 2025 Jun 8. Int J Clin Oncol. 2025. PMID: 40483656 Free PMC article. Review.
-
Long-term safety of high-dose whole pelvic IMRT for high-risk localized prostate cancer through 10-year follow-up.Int J Clin Oncol. 2021 Nov;26(11):2113-2122. doi: 10.1007/s10147-021-02002-x. Epub 2021 Aug 2. Int J Clin Oncol. 2021. PMID: 34338920
Publication types
LinkOut - more resources
Full Text Sources
